GV

Tracked participation in 9 Atlas companies, with 6 explicitly attributed leads.

Firm website ↗

9portfolio companies

22round participations

6lead positions

$1.3Bled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

May 2026SierraSeries E$950Mat $15B valuation Jul 2024HarveySeries C$100Mat $1.5B valuation Jul 2024OdysseySeed$9M Dec 2023LightmatterSeries C-2$155Mat $1.2B valuation Feb 2019LightmatterSeries A-1$22M Mar 2018SambaNovaSeries A$56M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—Mar 2019 → null3 roundsParticipant—

OOdyssey$1.5BJul 2024 → Jun 20263 rounds1 led—

ILIsomorphic Labs—Mar 2025 → May 20262 roundsParticipant—

SSierra$15BMay 2026 → May 20261 round1 led—

SSambaNova$5.1BMar 2018 → Feb 20263 rounds1 led—

WWaymoPhysical AIWaymo (Waymo LLC) is an Alphabet subsidiary developing and operating commercial, fully autonomous driving technology…$126Bvaluation$26.4BraisedRecent roundsInvestment round (led by Dragoneer; majority investor Alphabet) · Feb 2026$16B · led by Dragoneer Investment Group, DST Global +1Oversubscribed investment round · Oct 2024$5.6B · led by AlphabetInvestment round · Jun 2021$2.5B · Alphabet, Andreessen Horowitz +10Waymo$126BFeb 2026 → Feb 20261 roundParticipant—

HHarveyApplicationsHarvey (harvey.ai) is a legal-focused AI platform for professional services that combines purpose-built “agentic”…$15.5Bvaluation$1.8BraisedRecent roundsFunding round · Sep 2026$550M · led by Diffusion, Lightspeed Venture PartnersStrategic investment (equity) · Jul 2026Goldman Sachs Alternatives (Growth Equity), J.P. Morgan Growth Equity PartnersGrowth round · Mar 2026$200M · led by GIC, Sequoia CapitalHarvey$5BJul 2024 → Jun 20253 rounds1 led—

SSynthesia$2.1BDec 2021 → Jan 20253 roundsParticipant—

LLightmatter$1.2BFeb 2019 → Dec 20233 rounds2 ledTyson Clark

DateCompanyRoundRaisedValuationRoleEvidence

nullOOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinTotal disclosed (company press kit aggregate)$304.1M—Participant